For example, resistance to Trastuzumab (in treatment of HER-2 positive breast cancer) can be due to upregulation of signaling pathways downstream to HER-2, as a result of PTEN loss, or mutations in PI3K or AKT1 [10]. This evidence concerns the gene ERBB2 and breast cancer.